ICPT - Intercept Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
95.68
-0.32 (-0.33%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous close96.00
Open96.25
Bid82.80 x 1300
Ask97.00 x 800
Day's range94.61 - 96.90
52-week range51.05 - 135.59
Volume338,151
Avg. volume606,866
Market cap2.831B
Beta2.03
PE ratio (TTM)N/A
EPS (TTM)-14.00
Earnings date30 Jul 2018 - 3 Aug 2018
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est107.07
Trade prices are not sourced from all markets
  • 3 Biotech Stocks With Big News Coming in NASH
    Motley Fool5 days ago

    3 Biotech Stocks With Big News Coming in NASH

    The next big market for biopharma could be nonalcoholic steatohepatitis, so upcoming data from these companies could be market-moving.

  • This Is the Most Undervalued NASH Drug Stock, and Wall Street Is Ignoring It
    Motley Fool23 days ago

    This Is the Most Undervalued NASH Drug Stock, and Wall Street Is Ignoring It

    This NASH drug developer has a decent chance at beating all of its peers to market.

  • 3 Top Biotech Stocks to Buy Right Now
    Motley Foollast month

    3 Top Biotech Stocks to Buy Right Now

    These drug stocks are prescribing some serious growth potential in the years to come.

  • NASH Space in Focus as Galmed (GLMD) Posts Positive Data
    Zackslast month

    NASH Space in Focus as Galmed (GLMD) Posts Positive Data

    Investor focus is back on the NASH space as quite a few companies release promising data on their NASH candidates of late.

  • GlobeNewswirelast month

    Intercept to Present at Upcoming Conference

    NEW YORK, June 07, 2018-- Intercept Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, ...

  • Intercept (ICPT) Up 3.8% Since Earnings Report: Can It Continue?
    Zackslast month

    Intercept (ICPT) Up 3.8% Since Earnings Report: Can It Continue?

    Intercept (ICPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Madrigal's NASH Study Data Encouraging, Stock Skyrockets
    Zacks2 months ago

    Madrigal's NASH Study Data Encouraging, Stock Skyrockets

    Madrigal Pharmaceuticals' (MDGL) thyroid hormone receptor, MGL-3196, achieves significantly sustained reduction in liver fat at week 36 in a phase II study evaluating it in NASH patients.

  • Analysts Are Bullish on Viking Therapeutics Stock
    Market Realist2 months ago

    Analysts Are Bullish on Viking Therapeutics Stock

    Viking Therapeutics’ (VKTX) stock price rose ~101% on May 31 following the successful trial results of Madrigal Pharmaceuticals’ (MDGL) NASH drug. Madrigal Pharmaceuticals’ drug has a similar mechanism of action as Viking Pharmaceuticals’ NASH drug. In this part, we’ll discuss Wall Street analysts’ recommendations for Viking Therapeutics stock in the next 12 months.

  • GlobeNewswire2 months ago

    Report: Developing Opportunities within AG Mortgage Investment Trust, Associated Banc-Corp, Reata Pharmaceuticals, Nathan's Famous, United Fire Group, and Intercept Pharmaceuticals — Future Expectations, Projections Moving into 2018

    NEW YORK, May 18, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of AG ...

  • Intercept (ICPT) Q1 Loss Narrower Than Expected, Sales Lag
    Zacks2 months ago

    Intercept (ICPT) Q1 Loss Narrower Than Expected, Sales Lag

    Intercept's (ICPT) first-quarter results were mixed as loss was narrower than expectations but sales missed expectations. The company also provided Ocaliva sales guidance for 2018.

  • Associated Press2 months ago

    Intercept: 1Q Earnings Snapshot

    The New York-based company said it had a loss of $3.22 per share. The results topped Wall Street expectations. The average estimate of eight analysts surveyed by Zacks Investment Research was for a loss ...

  • GlobeNewswire2 months ago

    Intercept Pharmaceuticals Announces First Quarter 2018 Financial Results, Issues 2018 Ocaliva Net Sales Guidance and Provides Business Update

    Intercept Pharmaceuticals, Inc. (ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced its financial results for the quarter ended March 31, 2018. “We are pleased with our progress to date in 2018, as we continue to work to strengthen our leadership position in NASH and remain on track for the top line readout of data from our Phase 3 REGENERATE trial in the first half of 2019. Based on our review of the evolving competitive landscape, the new data released at the recent International Liver Congress in Paris and the strength of OCA’s Phase 2 and other data, we continue to believe in OCA’s significant potential in NASH,” said Mark Pruzanski, M.D., President and Chief Executive Officer of Intercept.

  • GlobeNewswire3 months ago

    Intercept to Announce First Quarter 2018 Financial Results on May 8, 2018 and Present at Upcoming Investor Conferences

    NEW YORK, May 01, 2018-- Intercept Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, ...

  • What's in Store for Intercept (ICPT) This Earnings Season?
    Zacks3 months ago

    What's in Store for Intercept (ICPT) This Earnings Season?

    Investors are expected to focus on Ocaliva sales when Intercept (ICPT) reports first-quarter results (expected on May 3).

  • Analysts’ Ratings for Amicus and Its Peers in April
    Market Realist3 months ago

    Analysts’ Ratings for Amicus and Its Peers in April

    Amicus Therapeutics (FOLD) is a global patient-focused biotechnology company engaged in developing and commercializing diverse novel treatments for patients with rare metabolic diseases. As of April 2018, of the seven analysts covering Amicus Therapeutics, three have given the stock “strong buy” ratings, three have given it “buy” ratings, and one has given it a “hold” rating. The mean rating for the stock is 1.71 with a target price of $19.93, implying an upside of almost 45% to $13.79 as of its closing on April 24.

  • GlobeNewswire3 months ago

    Intercept Pharmaceuticals Appoints Nancy Miller-Rich to Its Board of Directors

    NEW YORK, April 24, 2018-- Intercept Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, ...

  • How Analysts Rate Regenxbio and Peers in April 2018
    Market Realist3 months ago

    How Analysts Rate Regenxbio and Peers in April 2018

    Regenxbio (RGNX) is a clinical-stage biotechnology company focused on developing gene therapy product candidates to address genetic defects. The company’s product candidate RGX-314 is designed for the treatment of wet age-related macular degeneration (or wet AMD), which is a leading cause of total and partial vision loss in the US, Europe, and Japan. The other promising product candidate in Regenxbio’s pipeline is RGX-501 for the treatment of homozygous familial hypercholesterolemia (or HoFH).

  • Could This Tiny Biotech Rout Intercept In Liver Disease Drugs?
    Investor's Business Daily3 months ago

    Could This Tiny Biotech Rout Intercept In Liver Disease Drugs?

    CymaBay launched to a month-high Wednesday after unveiling strong data for a liver disease treatment — to the detriment of Intercept which has struggled with its rival drug.

  • A Look at Intercept Pharmaceuticals’ Cash Flows
    Market Realist3 months ago

    A Look at Intercept Pharmaceuticals’ Cash Flows

    Intercept Pharmaceuticals (ICPT) spent $265.4 million on operating activities in fiscal 2017 compared with $342.4 million in fiscal 2016. In fiscal 2017, Intercept Pharmaceuticals generated $2.8 million from financing activities, which were mainly from the exercise of options to purchase common stock. On April 5, 2018, Intercept Pharmaceuticals announced pricing of the upsized $250 million public offering of its common stock with a concurrent private placement of 1.5 million of its common shares.

  • 4 Top Stocks for Investing in Pharma's Next $35 Billion Market
    Motley Fool3 months ago

    4 Top Stocks for Investing in Pharma's Next $35 Billion Market

    A NASH dash is on -- and these drugmakers could come out on top.

  • Analysts’ Ratings for Enanta Pharmaceuticals and Peers in April
    Market Realist3 months ago

    Analysts’ Ratings for Enanta Pharmaceuticals and Peers in April

    Enanta Pharmaceuticals (ENTA) is a biotechnology company with a chemistry-driven approach. Enanta Pharmaceuticals discovered glecaprevir, a protease inhibitor for the treatment of chronic hepatitis C virus (or HCV). Enanta’s second protease inhibitor under its collaboration with AbbVie is marketed under the tradename Viekera Pak under AbbVie’s initial DAA regimens for the treatment of chronic HCV.

  • Analysts’ Ratings For Acorda Therapeutics in April 2018
    Market Realist3 months ago

    Analysts’ Ratings For Acorda Therapeutics in April 2018

    Acorda Therapeutics (ACOR), a biopharmaceutical company, develops therapies for neurological disorders. Of the ten analysts covering Acorda Therapeutics in April 2018, three have recommended “buy,” six have recommended “hold,” and one has recommended “sell.” Their mean rating for the stock is 2.8, and their target price is $24.78. Of the 20 analysts covering Intercept Pharmaceuticals (ICPT) in April 2018, ten have recommended “buy” or a higher rating, seven have recommended “hold,” and three have recommended “sell.” The mean rating for the stock is 2.5, and its target price is $110.91.

  • The Financial Performance of Intercept Pharmaceuticals
    Market Realist3 months ago

    The Financial Performance of Intercept Pharmaceuticals

    Intercept Pharmaceuticals: An Investor’s Overview

  • 3 High-Growth Stocks That Could Soar
    Motley Fool3 months ago

    3 High-Growth Stocks That Could Soar

    Looking for stocks with explosive growth potential? Check these out.